An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women With High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 4
- 主要终点
- Safety/tolerability
研究概览
简要总结
This is an exploratory, open, prospective multi-centre study of VB10.16 immunotherapy in patients with high grade HPV16+ Cervical Intraepithelial Neoplasia (HSIL; CIN2/3). This study will recruit approximately 27-40 female patients with high grade cervical intraepithelial neoplasia (HSIL, CIN 2/3) at multiple sites in Europe.
详细描述
The study will be divided into two phases, a dosing and expansion phase.
During the dosing phase the safety, tolerability and immunogenicity of 2 different vaccination schedules of 3 mg VB10.16 immunotherapy will be established in a minimum of 12 patients with histology confirmed CIN 2.
During the expansion phase the safety, tolerability and immunogenicity of the selected vaccination schedule will be evaluated in approximately 15 to 20 patients with histology confirmed HPV16+ CIN 2/3.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •(abbreviated):
- •Women ≥18 years
- •Women with ectocervical HPV16+ associated High Grade Cervical Intraepithelial Neoplasia (HSIL) as verified by local pathology:
- •(Dosing Phase: Women with histologically confirmed HPV16+ associated CIN 2; Expansion Phase: Women with histologically confirmed HPV16+ associated CIN 2/3)
- •Satisfactory colposcopic examination.
排除标准
- •(abbreviated):
- •More than 2 cervical quadrants of CIN 3 as visualised by colposcopy.
- •Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology, malignant cells on cytology or histology or other suspicion of either micro-invasive or invasive disease.
- •Current severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological infection as per colposcopy and clinical examination.
- •Positive serological test for hepatitis C virus or hepatitis B virus surface antigen (HBsAg) or human immunodeficiency virus (HIV).
- •Administration of any blood product within 3 months of enrolment.
- •Concomitant or prior malignant disease.
- •Clinically significant autoimmune disease.
- •Known allergy to Kanamycin or other aminoglycosides
- •Known immunodeficiency and or immunosuppression.
- •History of toxic shock syndrome.
- •Evidence or history of clinically significant cardiac disease
- •Active infection requiring parenteral antibiotics.
- •Tattoos, scars, or active lesions/rashes within 2 cm of the site of vaccination or any implantable leads.
- •Immunosuppression
- •Major surgery within 3 months of trial entry.
- •Current or recent (within 30 days of first study treatment) participation in a clinical trial.
- •Previous vaccination (either therapeutic and/or prophylactic) against HPV.
- •Administration of any live vaccine within 90 days of trial entry.
- •Concomitant anticancer therapies.
- •Inadequate bone marrow function
- •Inadequate liver function
- •Clinical significant electrolyte abnormalities
- •Women of childbearing age not willing to use an effective form of contraception
- •Pregnancy or intention to become pregnant
- •Nursing women
- •Evidence of any other medical condition that may interfere with study participation, patient compliance or place the patient at high risk from treatment-related complications
研究组 & 干预措施
Cohort 1: 3mg VB10.16 Vaccine
VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 3, Week 6, 3mgs per vaccination
干预措施: VB10.16 Immunotherapy (DNA vaccine) (Biological)
Cohort 2: 3mg VB10.16 Vaccine
VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 4, Week 8, 3mgs per vaccination
干预措施: VB10.16 Immunotherapy (DNA vaccine) (Biological)
结局指标
主要结局
Safety/tolerability
时间窗: 6 months (extended follow up for additional 6 months)
- The percentage of patients with adverse events (AEs), including any dose-limiting toxicities (DLT), laboratory assessments and physical findings.
次要结局
- Immunogenicity(6 months)
- Preliminary assessment of efficacy(6 months (extended follow up for additional 6 months))